After Bristol-Myers Squibb Co. declined to exercise its option to buy Promedior Inc. in mid-2018, the small biopharmaceutical company began to consider its options for financing Phase III development of its lead asset PRM-151 in idiopathic pulmonary fibrosis (IPF). Ultimately, Promedior opted to be acquired by another big pharma, announcing on 15 November that Roche will pay $390m up front and up to $1bn in development, regulatory and commercial milestone fees.
CEO and Lightstone Ventures general partner Jason Lettman told Scrip that Promedior has had an eventful year since the presentation...








